Pacira BioSciences Key Executives
This section highlights Pacira BioSciences's key executives, including their titles and compensation details.
Find Contacts at Pacira BioSciences
(Showing 0 of )
Pacira BioSciences Earnings
This section highlights Pacira BioSciences's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-27 | $0.78 | $0.91 |
| Read Transcript | Q3 | 2024 | 2024-11-06 | $0.72 | $0.79 |
| Read Transcript | Q2 | 2024 | 2024-07-30 | $0.73 | $0.89 |
| Read Transcript | Q1 | 2024 | 2024-05-07 | $0.64 | $0.62 |
| Read Transcript | Q4 | 2023 | 2024-02-29 | $0.89 | $0.89 |
| Read Transcript | Q3 | 2023 | 2023-11-02 | $0.84 | $0.72 |
| Read Transcript | Q2 | 2023 | 2023-08-02 | $0.81 | $0.78 |
| Read Transcript | Q1 | 2023 | 2023-05-03 | $0.60 | $0.53 |
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
$25.89
Stock Price
$1.20B
Market Cap
790
Employees
Tampa, FL
Location
Financial Statements
Access annual & quarterly financial statements for Pacira BioSciences, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $700.97M | $674.98M | $666.82M | $541.53M | $420.83M |
| Cost of Revenue | $- | $184.67M | $199.29M | $140.25M | $117.33M |
| Gross Profit | $700.97M | $490.31M | $467.53M | $401.28M | $303.50M |
| Gross Profit Ratio | 100.00% | 72.64% | 70.11% | 74.10% | 72.12% |
| Research and Development Expenses | $81.58M | $76.26M | $84.80M | $55.55M | $59.42M |
| General and Administrative Expenses | $122.08M | $116.40M | $109.52M | $88.32M | $74.83M |
| Selling and Marketing Expenses | $172.01M | $153.04M | $145.00M | $111.02M | $118.68M |
| Selling General and Administrative Expenses | $294.10M | $269.44M | $254.52M | $199.34M | $193.52M |
| Other Expenses | $398.66M | $56.94M | $57.29M | $13.55M | $7.87M |
| Operating Expenses | $774.34M | $402.63M | $396.60M | $268.44M | $260.80M |
| Cost and Expenses | $774.34M | $587.30M | $595.90M | $408.70M | $378.13M |
| Interest Income | $19.69M | $11.44M | $4.54M | $896.00K | $4.63M |
| Interest Expense | $13.44M | $20.31M | $39.98M | $31.75M | $25.67M |
| Depreciation and Amortization | $78.78M | $75.57M | $91.50M | $28.55M | $19.91M |
| EBITDA | $29.12M | $157.58M | $144.78M | $118.47M | $71.42M |
| EBITDA Ratio | 4.15% | 23.35% | 21.71% | 21.88% | 16.97% |
| Operating Income | $-73.37M | $87.67M | $60.02M | $131.06M | $46.35M |
| Operating Income Ratio | -10.47% | 12.99% | 9.00% | 24.20% | 11.01% |
| Total Other Income Expenses Net | $10.27M | $-25.97M | $-46.72M | $-33.52M | $-26.26M |
| Income Before Tax | $-63.11M | $61.70M | $13.30M | $56.40M | $20.09M |
| Income Before Tax Ratio | -9.00% | 9.14% | 1.99% | 10.42% | 4.77% |
| Income Tax Expense | $36.45M | $19.75M | $-2.61M | $14.42M | $-125.43M |
| Net Income | $-99.56M | $41.95M | $15.91M | $41.98M | $145.52M |
| Net Income Ratio | -14.20% | 6.22% | 2.39% | 7.75% | 34.58% |
| EPS | $-2.15 | $0.91 | $0.35 | $0.95 | $3.41 |
| EPS Diluted | $-2.15 | $0.81 | $0.34 | $0.92 | $3.33 |
| Weighted Average Shares Outstanding | 46.24M | 46.22M | 45.52M | 44.26M | 42.67M |
| Weighted Average Shares Outstanding Diluted | 46.24M | 51.98M | 46.54M | 45.63M | 43.68M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $187.25M | $168.57M | $178.02M | $167.12M | $181.24M | $163.93M | $169.47M | $160.34M | $171.96M | $167.47M | $169.41M | $157.99M | $159.19M | $127.72M | $135.59M | $119.03M | $128.55M | $117.48M | $75.50M | $105.68M |
| Cost of Revenue | $39.89M | $38.86M | $58.58M | $61.74M | $62.01M | $39.75M | $48.21M | $49.02M | $61.92M | $50.68M | $50.63M | $36.07M | $39.01M | $34.65M | $35.25M | $31.35M | $35.30M | $29.99M | $22.30M | $29.73M |
| Gross Profit | $147.37M | $129.71M | $119.44M | $105.38M | $119.23M | $124.18M | $121.26M | $111.32M | $110.04M | $116.79M | $118.78M | $121.92M | $120.19M | $93.07M | $100.34M | $87.68M | $93.25M | $87.49M | $53.20M | $75.95M |
| Gross Profit Ratio | 78.70% | 76.95% | 67.09% | 63.06% | 65.78% | 75.75% | 71.55% | 69.43% | 63.99% | 69.74% | 70.12% | 77.17% | 75.50% | 72.87% | 74.00% | 73.66% | 72.54% | 74.47% | 70.46% | 71.87% |
| Research and Development Expenses | $23.90M | $19.10M | $20.34M | $18.24M | $19.46M | $20.83M | $18.82M | $17.14M | $17.50M | $19.41M | $26.28M | $21.61M | $15.51M | $11.58M | $12.57M | $15.88M | $15.33M | $14.65M | $13.62M | $15.82M |
| General and Administrative Expenses | $29.27M | $31.14M | $29.08M | $32.59M | $30.06M | $29.69M | $27.39M | $29.26M | $27.97M | $27.58M | $28.15M | $25.82M | $21.84M | $22.51M | $22.55M | $21.42M | $20.63M | $19.35M | $17.99M | $16.87M |
| Selling and Marketing Expenses | $50.34M | $43.19M | $39.05M | $39.44M | $35.74M | $38.26M | $37.46M | $41.58M | $36.00M | $33.71M | $36.85M | $38.44M | $29.36M | $26.30M | $28.26M | $27.10M | $32.20M | $33.22M | $25.36M | $27.91M |
| Selling General and Administrative Expenses | $79.61M | $74.33M | $68.13M | $72.03M | $65.80M | $67.95M | $64.85M | $70.84M | $63.97M | $61.28M | $65.00M | $64.26M | $52.15M | $48.81M | $50.81M | $48.52M | $52.83M | $52.56M | $43.34M | $44.78M |
| Other Expenses | $19.15M | $175.80M | $-39.00K | $-159.00K | $515.00K | $-422.00K | $-269.00K | $14.32M | $14.32M | $14.32M | $14.32M | $14.32M | $-65.00K | $-46.00K | $-2.40M | $-157.00K | $279.00K | $2.71M | $3.97M | $-4.10M |
| Operating Expenses | $122.66M | $269.24M | $88.46M | $90.26M | $85.26M | $103.10M | $98.00M | $102.31M | $95.80M | $95.01M | $105.61M | $100.19M | $75.32M | $62.35M | $65.35M | $66.37M | $70.13M | $69.18M | $58.93M | $62.57M |
| Cost and Expenses | $162.55M | $308.10M | $147.05M | $152.00M | $147.28M | $142.85M | $146.20M | $151.32M | $157.71M | $145.69M | $156.23M | $136.26M | $114.33M | $97.00M | $100.60M | $97.72M | $105.43M | $99.17M | $81.23M | $92.30M |
| Interest Income | $5.55M | $5.48M | $4.75M | $3.90M | $3.42M | $2.77M | $2.11M | $3.14M | $2.79M | $1.23M | $252.00K | $271.00K | $79.00K | $177.00K | $224.00K | $415.00K | $693.00K | $1.02M | $1.32M | $1.59M |
| Interest Expense | $3.83M | $3.85M | $3.12M | $2.63M | $4.10M | $3.46M | $3.87M | $9.59M | $11.04M | $8.95M | $7.96M | $9.07M | $10.42M | $6.67M | $6.36M | $6.32M | $7.06M | $7.13M | $5.46M | $5.58M |
| Depreciation and Amortization | $21.24M | $20.25M | $18.86M | $18.43M | $18.48M | $18.43M | $19.05M | $19.60M | $30.41M | $20.20M | $20.86M | $20.03M | $13.07M | $5.77M | $4.87M | $4.85M | $1.97M | $1.97M | $1.97M | $4.82M |
| EBITDA | $50.60M | $-114.75M | $49.84M | $35.38M | $52.45M | $39.51M | $42.32M | $2.72M | $23.38M | $41.98M | $34.04M | $41.76M | $60.94M | $37.33M | $37.54M | $26.16M | $30.61M | $23.35M | $3.11M | $16.11M |
| EBITDA Ratio | 27.02% | -68.07% | 28.00% | 21.17% | 28.94% | 24.10% | 24.97% | 1.69% | 13.60% | 25.07% | 20.09% | 26.43% | 38.28% | 29.23% | 27.68% | 21.98% | 23.81% | 19.87% | 4.12% | 15.24% |
| Operating Income | $24.70M | $-139.53M | $30.98M | $15.12M | $33.97M | $17.72M | $39.88M | $12.15M | $17.11M | $11.51M | $11.91M | $17.39M | $4.21M | $31.43M | $34.84M | $19.44M | $18.78M | $17.62M | $-7.15M | $17.09M |
| Operating Income Ratio | 13.19% | -82.77% | 17.40% | 9.04% | 18.74% | 10.81% | 23.53% | 7.58% | 9.95% | 6.87% | 7.03% | 11.01% | 2.65% | 24.61% | 25.70% | 16.33% | 14.61% | 15.00% | -9.47% | 16.17% |
| Total Other Income Expenses Net | $822.00K | $671.00K | $8.34M | $-1.48M | $552.00K | $-1.12M | $-2.02M | $-23.38M | $-8.18M | $-19.22M | $-9.23M | $-10.10M | $-10.41M | $-7.20M | $-9.20M | $-6.71M | $-6.09M | $-11.47M | $-164.00K | $-8.54M |
| Income Before Tax | $25.53M | $-138.86M | $36.58M | $13.64M | $33.72M | $16.60M | $37.85M | $-26.47M | $-18.07M | $2.07M | $22.01M | $7.29M | $-6.20M | $24.23M | $25.65M | $12.72M | $12.69M | $6.15M | $-7.31M | $8.56M |
| Income Before Tax Ratio | 13.63% | -82.37% | 20.55% | 8.16% | 18.60% | 10.13% | 22.34% | -16.51% | -10.51% | 1.24% | 12.99% | 4.62% | -3.89% | 18.97% | 18.92% | 10.69% | 9.87% | 5.23% | -9.68% | 8.10% |
| Income Tax Expense | $9.48M | $4.61M | $17.70M | $4.66M | $8.85M | $5.74M | $12.09M | $-6.94M | $-7.97M | $2.76M | $2.13M | $466.00K | $-1.07M | $6.57M | $6.57M | $2.35M | $-1.82M | $-123.97M | $-42.00K | $398.00K |
| Net Income | $16.04M | $-143.47M | $18.89M | $8.98M | $24.87M | $10.86M | $25.76M | $-19.54M | $-10.10M | $-693.00K | $19.88M | $6.83M | $-5.13M | $17.66M | $19.08M | $10.37M | $14.51M | $130.12M | $-7.27M | $8.16M |
| Net Income Ratio | 8.57% | -85.11% | 10.61% | 5.37% | 13.72% | 6.62% | 15.20% | -12.18% | -5.87% | -0.41% | 11.73% | 4.32% | -3.22% | 13.83% | 14.07% | 8.71% | 11.29% | 110.75% | -9.63% | 7.72% |
| EPS | $0.35 | $-3.11 | $0.41 | $0.19 | $0.54 | $0.23 | $0.56 | $-0.43 | $-0.22 | $-0.02 | $0.40 | $0.15 | $-0.12 | $0.40 | $0.43 | $0.24 | $0.33 | $3.03 | $-0.17 | $0.19 |
| EPS Diluted | $0.35 | $-3.11 | $0.39 | $0.19 | $0.48 | $0.23 | $0.49 | $-0.43 | $-0.22 | $-0.02 | $0.38 | $0.15 | $-0.12 | $0.39 | $0.42 | $0.23 | $0.32 | $2.94 | $-0.17 | $0.19 |
| Weighted Average Shares Outstanding | 46.19M | 46.13M | 46.17M | 46.50M | 46.44M | 46.42M | 46.09M | 45.95M | 45.88M | 45.83M | 49.87M | 44.87M | 44.59M | 44.48M | 44.15M | 43.83M | 43.50M | 42.93M | 42.22M | 42.03M |
| Weighted Average Shares Outstanding Diluted | 46.19M | 46.13M | 50.54M | 52.19M | 52.06M | 52.07M | 52.05M | 45.95M | 45.88M | 45.83M | 52.48M | 46.44M | 44.59M | 45.46M | 45.59M | 45.97M | 44.73M | 44.27M | 42.22M | 42.78M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $276.77M | $153.30M | $104.14M | $585.58M | $99.96M |
| Short Term Investments | $- | $125.28M | $184.51M | $70.83M | $421.70M |
| Cash and Short Term Investments | $276.77M | $278.58M | $288.65M | $656.41M | $521.66M |
| Net Receivables | $113.30M | $105.56M | $98.40M | $96.32M | $53.05M |
| Inventory | $125.28M | $104.35M | $96.06M | $98.55M | $64.65M |
| Other Current Assets | $229.77M | $21.50M | $15.22M | $29.44M | $12.27M |
| Total Current Assets | $745.13M | $509.99M | $498.33M | $866.05M | $651.62M |
| Property Plant Equipment Net | $216.39M | $234.95M | $254.39M | $264.81M | $211.18M |
| Goodwill | $- | $163.24M | $163.24M | $145.18M | $99.55M |
| Intangible Assets | $425.97M | $483.26M | $540.55M | $623.97M | $96.52M |
| Goodwill and Intangible Assets | $425.97M | $646.50M | $703.79M | $769.14M | $196.07M |
| Long Term Investments | $35.65M | $2.41M | $64.38M | $21.99M | $109.48M |
| Tax Assets | $130.38M | $144.49M | $160.31M | $153.36M | $106.16M |
| Other Non-Current Assets | $- | $36.05M | $- | $- | $- |
| Total Non-Current Assets | $808.39M | $1.06B | $1.18B | $1.21B | $622.89M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $1.55B | $1.57B | $1.68B | $2.08B | $1.27B |
| Account Payables | $19.13M | $15.70M | $15.22M | $10.54M | $10.43M |
| Short Term Debt | $8.89M | $17.44M | $51.89M | $382.59M | $157.07M |
| Tax Payables | $- | $- | $- | $429.00K | $114.00K |
| Deferred Revenue | $- | $- | $- | $10.12M | $71.09M |
| Other Current Liabilities | $281.90M | $64.24M | $80.66M | $127.56M | $85.71M |
| Total Current Liabilities | $309.92M | $97.38M | $147.77M | $521.12M | $253.33M |
| Long Term Debt | $481.11M | $568.60M | $720.62M | $746.26M | $384.06M |
| Deferred Revenue Non-Current | $- | $- | $- | $10.12M | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $38.27M | $37.79M | $67.44M | $17.44M |
| Total Non-Current Liabilities | $481.11M | $606.87M | $758.42M | $823.83M | $401.50M |
| Other Liabilities | $-15.86M | $- | $- | $- | $- |
| Total Liabilities | $775.17M | $704.26M | $906.19M | $1.34B | $654.83M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $47.00K | $46.00K | $46.00K | $45.00K | $44.00K |
| Retained Earnings | $-206.36M | $-106.80M | $-148.75M | $-211.90M | $-253.88M |
| Accumulated Other Comprehensive Income Loss | $343.00K | $247.00K | $-380.00K | $167.00K | $318.00K |
| Other Total Stockholders Equity | $984.31M | $976.63M | $924.10M | $942.09M | $873.20M |
| Total Stockholders Equity | $778.35M | $870.13M | $775.01M | $730.41M | $619.69M |
| Total Equity | $778.35M | $870.13M | $775.01M | $730.41M | $619.69M |
| Total Liabilities and Stockholders Equity | $1.55B | $1.57B | $1.68B | $2.08B | $1.27B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $1.55B | $1.57B | $1.68B | $2.08B | $1.27B |
| Total Investments | $35.65M | $127.69M | $248.89M | $92.82M | $531.18M |
| Total Debt | $490.00M | $586.04M | $763.39M | $1.13B | $541.13M |
| Net Debt | $213.22M | $432.75M | $659.25M | $543.27M | $441.17M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $276.77M | $245.97M | $247.05M | $184.05M | $153.30M | $99.12M | $86.81M | $35.55M | $104.14M | $109.42M | $122.06M | $226.75M | $585.58M | $134.04M | $105.77M | $66.70M | $99.96M | $125.24M | $78.55M | $54.59M |
| Short Term Investments | $207.84M | $207.84M | $157.17M | $141.84M | $125.28M | $136.07M | $133.96M | $138.45M | $184.51M | $219.30M | $194.33M | $225.44M | $70.83M | $559.82M | $540.82M | $523.36M | $421.70M | $406.88M | $248.24M | $263.88M |
| Cash and Short Term Investments | $484.62M | $453.81M | $404.23M | $325.89M | $278.58M | $235.19M | $220.77M | $174.00M | $288.65M | $328.73M | $316.39M | $452.19M | $656.41M | $693.86M | $646.60M | $590.06M | $521.66M | $532.12M | $335.05M | $318.46M |
| Net Receivables | $113.30M | $100.65M | $104.78M | $101.64M | $105.56M | $96.96M | $99.08M | $93.20M | $98.40M | $93.47M | $91.11M | $92.10M | $96.32M | $49.98M | $68.36M | $52.58M | $53.05M | $46.14M | $44.01M | $38.99M |
| Inventory | $125.28M | $111.86M | $103.44M | $96.78M | $104.35M | $96.52M | $92.13M | $92.98M | $96.06M | $96.80M | $100.59M | $103.66M | $98.55M | $67.21M | $65.26M | $64.61M | $64.65M | $68.54M | $66.69M | $59.67M |
| Other Current Assets | $21.93M | $23.64M | $19.77M | $18.80M | $21.50M | $18.59M | $17.35M | $15.93M | $15.22M | $14.42M | $18.12M | $19.06M | $29.44M | $11.31M | $23.83M | $25.19M | $12.27M | $21.82M | $18.33M | $27.35M |
| Total Current Assets | $745.13M | $689.97M | $632.21M | $543.11M | $509.99M | $447.25M | $429.32M | $376.11M | $498.33M | $533.41M | $526.21M | $667.02M | $866.05M | $822.35M | $792.58M | $720.25M | $651.62M | $658.52M | $455.82M | $431.59M |
| Property Plant Equipment Net | $216.39M | $220.68M | $225.11M | $230.43M | $234.95M | $239.18M | $246.15M | $249.70M | $254.39M | $263.31M | $263.36M | $264.04M | $264.81M | $229.03M | $224.55M | $217.71M | $211.18M | $201.57M | $191.10M | $145.72M |
| Goodwill | $- | $- | $163.24M | $163.24M | $163.24M | $163.24M | $163.24M | $163.24M | $163.24M | $157.36M | $146.13M | $145.72M | $145.18M | $99.55M | $99.55M | $99.55M | $99.55M | $99.55M | $99.55M | $99.55M |
| Intangible Assets | $425.97M | $440.29M | $454.61M | $468.94M | $483.26M | $497.58M | $511.90M | $526.22M | $540.55M | $581.00M | $595.32M | $609.65M | $623.97M | $90.62M | $92.59M | $94.55M | $96.52M | $98.49M | $100.45M | $102.42M |
| Goodwill and Intangible Assets | $425.97M | $440.29M | $617.86M | $632.18M | $646.50M | $660.82M | $675.14M | $689.47M | $703.79M | $738.36M | $741.46M | $755.37M | $769.14M | $190.17M | $192.13M | $194.10M | $196.07M | $198.03M | $200.00M | $201.97M |
| Long Term Investments | $- | $36.73M | $36.50M | $36.54M | $2.41M | $35.55M | $35.62M | $40.57M | $64.38M | $43.75M | $35.81M | $35.77M | $21.99M | $21.19M | $17.97M | $51.02M | $109.48M | $58.02M | $19.19M | $42.10M |
| Tax Assets | $130.38M | $134.02M | $135.14M | $141.06M | $144.49M | $151.66M | $156.14M | $167.57M | $160.31M | $155.53M | $167.15M | $169.28M | $153.36M | $93.27M | $98.60M | $104.47M | $106.16M | $104.12M | $-10.93M | $-6.98M |
| Other Non-Current Assets | $35.65M | $- | $-1 | $-1 | $36.05M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $10.93M | $6.98M |
| Total Non-Current Assets | $808.39M | $831.72M | $1.01B | $1.04B | $1.06B | $1.09B | $1.11B | $1.15B | $1.18B | $1.20B | $1.21B | $1.22B | $1.21B | $533.65M | $533.25M | $567.30M | $622.89M | $561.75M | $410.29M | $389.79M |
| Other Assets | $- | $- | $1 | $1 | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $1.55B | $1.52B | $1.65B | $1.58B | $1.57B | $1.53B | $1.54B | $1.52B | $1.68B | $1.73B | $1.73B | $1.89B | $2.08B | $1.36B | $1.33B | $1.29B | $1.27B | $1.22B | $866.11M | $821.38M |
| Account Payables | $19.13M | $19.37M | $18.73M | $8.98M | $15.70M | $16.51M | $24.21M | $17.26M | $15.22M | $12.93M | $13.98M | $14.84M | $10.54M | $7.89M | $12.18M | $9.11M | $10.43M | $13.01M | $9.16M | $15.85M |
| Short Term Debt | $210.66M | $210.66M | $18.30M | $17.64M | $17.44M | $17.27M | $28.48M | $28.75M | $51.89M | $50.60M | $50.04M | $201.70M | $382.59M | $161.63M | $159.32M | $157.15M | $157.07M | $14.91M | $15.24M | $7.94M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $11.00K | $863.00K | $429.00K | $395.00K | $- | $721.00K | $114.00K | $- | $1.61M | $1.74M |
| Deferred Revenue | $- | $- | $- | $- | $- | $-8.64M | $-8.64M | $- | $- | $- | $- | $10.12M | $10.12M | $51.19M | $52.16M | $50.96M | $71.09M | $60.40M | $49.30M | $46.45M |
| Other Current Liabilities | $80.12M | $76.38M | $55.66M | $66.82M | $64.24M | $59.88M | $56.22M | $52.68M | $80.66M | $67.99M | $69.14M | $87.67M | $127.56M | $55.87M | $57.19M | $65.10M | $85.71M | $58.35M | $44.57M | $54.79M |
| Total Current Liabilities | $309.92M | $306.40M | $92.69M | $93.44M | $97.38M | $93.66M | $108.91M | $98.70M | $147.77M | $131.53M | $133.18M | $305.07M | $521.12M | $225.79M | $228.69M | $232.08M | $253.33M | $86.27M | $70.58M | $80.31M |
| Long Term Debt | $428.19M | $433.77M | $639.45M | $564.13M | $568.60M | $573.03M | $592.23M | $605.36M | $720.62M | $779.40M | $789.45M | $799.45M | $746.26M | $392.93M | $389.94M | $387.00M | $384.06M | $528.91M | $388.07M | $350.27M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $10.12M | $10.12M | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $37.06M | $31.94M | $35.41M | $33.58M | $38.27M | $36.22M | $33.27M | $51.32M | $37.79M | $53.32M | $54.72M | $67.25M | $67.44M | $18.68M | $20.03M | $17.64M | $17.44M | $20.39M | $19.31M | $16.76M |
| Total Non-Current Liabilities | $465.25M | $465.71M | $674.85M | $597.72M | $606.87M | $609.25M | $625.49M | $656.68M | $758.42M | $832.72M | $844.17M | $876.83M | $823.83M | $411.61M | $409.97M | $404.65M | $401.50M | $549.31M | $407.38M | $367.03M |
| Other Liabilities | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $775.17M | $772.11M | $767.54M | $691.16M | $704.26M | $702.91M | $734.41M | $755.38M | $906.19M | $964.24M | $977.35M | $1.18B | $1.34B | $637.40M | $638.66M | $636.73M | $654.83M | $635.58M | $477.96M | $447.34M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $142.65M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $46.00K |
| Common Stock | $47.00K | $47.00K | $47.00K | $47.00K | $46.00K | $46.00K | $46.00K | $46.00K | $46.00K | $46.00K | $46.00K | $45.00K | $45.00K | $45.00K | $44.00K | $44.00K | $44.00K | $43.00K | $43.00K | $42.00K |
| Retained Earnings | $-206.36M | $-222.40M | $-78.93M | $-97.82M | $-106.80M | $-131.67M | $-142.52M | $-168.29M | $-148.75M | $-138.65M | $-137.96M | $-157.83M | $-211.90M | $-206.76M | $-224.43M | $-243.51M | $-253.88M | $-268.39M | $-398.51M | $-391.24M |
| Accumulated Other Comprehensive Income Loss | $343.00K | $678.00K | $105.00K | $152.00K | $247.00K | $-10.00K | $-173.00K | $-137.00K | $-380.00K | $-670.00K | $-605.00K | $-527.00K | $167.00K | $153.00K | $181.00K | $172.00K | $318.00K | $847.00K | $1.49M | $-1.05M |
| Other Total Stockholders Equity | $984.31M | $971.25M | $958.06M | $989.78M | $976.63M | $963.18M | $950.63M | $936.42M | $924.10M | $909.40M | $895.15M | $867.89M | $942.09M | $925.17M | $911.37M | $894.11M | $873.20M | $852.19M | $785.12M | $766.28M |
| Total Stockholders Equity | $778.35M | $749.58M | $879.28M | $892.16M | $870.13M | $831.55M | $807.98M | $768.04M | $775.01M | $770.12M | $756.64M | $709.58M | $730.41M | $718.60M | $687.17M | $650.82M | $619.69M | $584.69M | $388.15M | $374.04M |
| Total Equity | $778.35M | $749.58M | $879.28M | $892.16M | $870.13M | $831.55M | $807.98M | $768.04M | $775.01M | $770.12M | $756.64M | $709.58M | $730.41M | $718.60M | $687.17M | $650.82M | $619.69M | $584.69M | $388.15M | $374.04M |
| Total Liabilities and Stockholders Equity | $1.55B | $1.52B | $1.65B | $1.58B | $1.57B | $1.53B | $1.54B | $1.52B | $1.68B | $1.73B | $1.73B | $1.89B | $2.08B | $1.36B | $1.33B | $1.29B | $1.27B | $1.22B | $866.11M | $821.38M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $1.55B | $1.52B | $1.65B | $1.58B | $1.57B | $1.53B | $1.54B | $1.52B | $1.68B | $1.73B | $1.73B | $1.89B | $2.08B | $1.36B | $1.33B | $1.29B | $1.27B | $1.22B | $866.11M | $821.38M |
| Total Investments | $207.84M | $244.57M | $157.17M | $141.84M | $127.69M | $171.62M | $169.58M | $146.74M | $248.89M | $263.05M | $230.14M | $261.21M | $92.82M | $581.01M | $558.79M | $574.39M | $531.18M | $464.90M | $267.43M | $305.97M |
| Total Debt | $638.85M | $644.42M | $648.60M | $581.78M | $586.04M | $590.30M | $620.71M | $625.16M | $763.39M | $821.64M | $831.36M | $1.00B | $1.13B | $554.56M | $549.27M | $544.15M | $541.13M | $536.37M | $395.69M | $354.24M |
| Net Debt | $362.08M | $398.46M | $401.54M | $397.73M | $432.75M | $491.18M | $533.90M | $589.62M | $659.25M | $712.21M | $709.30M | $774.40M | $543.27M | $420.52M | $443.49M | $477.45M | $441.17M | $411.12M | $317.14M | $299.65M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-99.56M | $41.95M | $15.91M | $41.98M | $145.52M |
| Depreciation and Amortization | $78.78M | $75.57M | $91.50M | $28.55M | $19.91M |
| Deferred Income Tax | $20.62M | $15.62M | $-7.95M | $10.87M | $-126.61M |
| Stock Based Compensation | $51.17M | $47.90M | $48.09M | $42.25M | $39.92M |
| Change in Working Capital | $- | $-45.78M | $-16.43M | $-18.67M | $-24.39M |
| Accounts Receivables | $-7.75M | $-7.16M | $-2.08M | $-10.43M | $-5.52M |
| Inventory | $-20.93M | $-8.29M | $2.49M | $-4.47M | $-6.35M |
| Accounts Payables | $3.08M | $916.00K | $6.27M | $-10.26M | $-3.31M |
| Other Working Capital | $- | $-31.24M | $-23.11M | $6.49M | $-9.21M |
| Other Non Cash Items | $138.37M | $19.39M | $14.15M | $20.75M | $22.68M |
| Net Cash Provided by Operating Activities | $189.39M | $154.65M | $145.27M | $125.72M | $77.03M |
| Investments in Property Plant and Equipment | $-10.64M | $-15.16M | $-30.08M | $-45.87M | $-37.80M |
| Acquisitions Net | $- | $- | $-32.00M | $-437.23M | $-1.16M |
| Purchases of Investments | $-252.21M | $-144.37M | $-400.69M | $-611.49M | $-546.52M |
| Sales Maturities of Investments | $179.57M | $237.07M | $237.58M | $1.08B | $307.87M |
| Other Investing Activities | $- | $- | $-32.00M | $-4.00M | $-239.81M |
| Net Cash Used for Investing Activities | $-83.28M | $77.54M | $-225.19M | $-20.79M | $-277.61M |
| Debt Repayment | $76.61M | $-180.76M | $-427.69M | $363.75M | $192.62M |
| Common Stock Issued | $- | $- | $27.34M | $26.66M | $47.76M |
| Common Stock Repurchased | $-25.00M | $-106.00K | $2.95M | $2.81M | $-33.09M |
| Dividends Paid | $- | $- | $- | $-2.67M | $-1.62M |
| Other Financing Activities | $-34.25M | $-2.16M | $26.17M | $16.94M | $31.30M |
| Net Cash Used Provided by Financing Activities | $17.36M | $-183.03M | $-401.53M | $380.69M | $222.30M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $123.48M | $49.16M | $-481.44M | $485.62M | $21.73M |
| Cash at End of Period | $276.77M | $153.30M | $104.14M | $585.58M | $99.96M |
| Cash at Beginning of Period | $153.30M | $104.14M | $585.58M | $99.96M | $78.23M |
| Operating Cash Flow | $189.39M | $154.65M | $145.27M | $125.72M | $77.03M |
| Capital Expenditure | $-10.64M | $-15.16M | $-30.08M | $-45.87M | $-37.80M |
| Free Cash Flow | $178.75M | $139.49M | $115.20M | $79.85M | $39.23M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $16.04M | $-143.47M | $18.89M | $8.98M | $24.87M | $10.86M | $25.76M | $-19.54M | $-10.10M | $-693.00K | $19.88M | $6.83M | $-5.13M | $17.66M | $19.08M | $10.37M | $14.52M | $130.12M | $-7.27M | $8.16M |
| Depreciation and Amortization | $21.24M | $20.25M | $18.86M | $18.43M | $18.48M | $18.43M | $19.05M | $19.60M | $30.41M | $20.20M | $20.86M | $20.03M | $13.07M | $5.73M | $4.90M | $4.85M | $5.06M | $5.04M | $4.99M | $4.82M |
| Deferred Income Tax | $3.51M | $1.11M | $12.54M | $3.46M | $6.60M | $4.91M | $11.44M | $-7.34M | $-10.84M | $702.00K | $2.16M | $29.00K | $-2.08M | $5.34M | $5.87M | $1.75M | $-126.61M | $-124.57M | $-3.98M | $3.99M |
| Stock Based Compensation | $12.27M | $13.23M | $12.52M | $13.15M | $12.42M | $12.53M | $10.96M | $11.99M | $12.68M | $12.68M | $11.54M | $11.19M | $10.89M | $10.79M | $10.46M | $10.11M | $10.90M | $10.95M | $9.22M | $8.85M |
| Change in Working Capital | $-24.33M | $-3.72M | $-4.38M | $8.11M | $-15.65M | $-8.20M | $-6.21M | $-15.72M | $-2.21M | $-867.00K | $-5.22M | $-8.14M | $-236.00K | $15.38M | $-13.50M | $-20.32M | $4.10M | $6.13M | $-15.11M | $-19.51M |
| Accounts Receivables | $-12.65M | $4.13M | $-3.14M | $3.92M | $-8.60M | $2.12M | $-5.88M | $5.19M | $-4.93M | $-2.37M | $998.00K | $4.21M | $-13.50M | $18.38M | $-15.77M | $462.00K | $-6.90M | $-2.13M | $-5.03M | $8.54M |
| Inventory | $-13.42M | $-8.43M | $-6.66M | $7.57M | $-7.83M | $-4.39M | $847.00K | $3.09M | $735.00K | $3.79M | $3.07M | $-5.11M | $-1.91M | $-1.95M | $-658.00K | $43.00K | $3.89M | $-1.85M | $-7.02M | $-1.37M |
| Accounts Payables | $-325.00K | $637.00K | $9.75M | $-6.98M | $-1.07M | $-7.70M | $7.05M | $2.63M | $1.59M | $-577.00K | $-847.00K | $6.11M | $-9.44M | $-2.98M | $3.51M | $-1.35M | $-2.19M | $2.40M | $-6.38M | $2.87M |
| Other Working Capital | $2.06M | $-62.00K | $-4.33M | $3.60M | $1.86M | $1.76M | $-8.24M | $-10.91M | $393.00K | $-1.71M | $-8.44M | $-13.35M | $24.61M | $1.93M | $-574.00K | $-19.47M | $9.30M | $7.71M | $3.33M | $-29.55M |
| Other Non Cash Items | $4.41M | $166.51M | $45.11M | $42.46M | $854.00K | $5.91M | $-17.50M | $30.13M | $22.10M | $10.63M | $-19.43M | $841.00K | $6.70M | $5.39M | $3.33M | $5.33M | $138.71M | $12.11M | $-3.48M | $-105.00K |
| Net Cash Provided by Operating Activities | $33.13M | $53.92M | $53.24M | $49.10M | $47.58M | $44.44M | $43.50M | $19.13M | $42.04M | $42.65M | $29.81M | $30.78M | $23.21M | $60.29M | $30.13M | $12.08M | $46.67M | $39.78M | $-15.62M | $6.21M |
| Investments in Property Plant and Equipment | $-2.12M | $-4.09M | $-1.59M | $-2.84M | $-1.80M | $-3.39M | $-3.40M | $-6.57M | $-5.49M | $-5.18M | $-11.73M | $-7.67M | $-9.17M | $-13.08M | $-10.55M | $-13.07M | $-14.41M | $-7.76M | $-8.91M | $-6.72M |
| Acquisitions Net | $- | $- | $- | $- | $-10.17M | $948.00K | $-10.73M | $-72.75M | $12.75M | $42.34M | $- | $-12.75M | $-420.04M | $-2.97M | $-9.06M | $1.22M | $-1.16M | $- | $- | $- |
| Purchases of Investments | $-45.20M | $-101.24M | $-49.73M | $-56.05M | $-25.93M | $-42.17M | $-22.77M | $-53.50M | $-68.26M | $-132.03M | $-44.79M | $-155.60M | $-98.00M | $-195.36M | $-130.26M | $-187.87M | $-219.85M | $-254.40M | $347.00K | $-72.61M |
| Sales Maturities of Investments | $46.95M | $53.16M | $36.10M | $43.36M | $36.10M | $41.23M | $33.50M | $126.25M | $84.94M | $89.70M | $62.94M | $- | $598.12M | $176.33M | $158.06M | $145.28M | $153.10M | $59.32M | $44.68M | $50.77M |
| Other Investing Activities | $- | $- | $-13.62M | $-12.69M | $10.17M | $-948.00K | $10.73M | $72.75M | $-12.75M | $-42.34M | $12.75M | $-32.00M | $-4.00M | $-22.00M | $-5.16M | $-1.22M | $-67.91M | $-195.08M | $45.03M | $-21.84M |
| Net Cash Used for Investing Activities | $-368.00K | $-52.16M | $-15.21M | $-15.53M | $8.37M | $-4.34M | $7.33M | $66.18M | $11.19M | $-47.52M | $19.16M | $-208.02M | $66.92M | $-35.08M | $3.03M | $-55.66M | $-82.32M | $-202.85M | $36.12M | $-28.57M |
| Debt Repayment | $-2.81M | $-2.81M | $85.05M | $-2.81M | $-2.81M | $-27.81M | $-2.81M | $-147.32M | $-59.38M | $-9.38M | $-166.34M | $-192.61M | $359.20M | $- | $- | $- | $- | $192.62M | $- | $- |
| Common Stock Issued | $- | $-1.36M | $1.36M | $- | $1.14M | $25.00K | $3.25M | $- | $2.04M | $1.60M | $12.68M | $11.02M | $6.03M | $3.05M | $7.25M | $10.32M | $45.22M | $- | $- | $- |
| Common Stock Repurchased | $- | $25.00M | $-25.00M | $-4.00K | $-106.00K | $- | $- | $- | $2.95M | $- | $- | $- | $- | $- | $- | $- | $166.28M | $-33.09M | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-2.67M | $- | $- | $- | $-1.62M | $- | $- | $- |
| Other Financing Activities | $857.00K | $-32.00K | $-60.07M | $-4.00K | $1.03M | $25.00K | $3.25M | $-6.91M | $864.00K | $1.60M | $12.68M | $11.02M | $-3.83M | $3.05M | $5.91M | $10.32M | $10.36M | $17.14M | $3.46M | $-1.28M |
| Net Cash Used Provided by Financing Activities | $-1.96M | $-2.85M | $24.98M | $-2.82M | $-1.78M | $-27.79M | $440.00K | $-153.91M | $-58.51M | $-7.78M | $-153.66M | $-181.59M | $361.41M | $3.05M | $5.91M | $10.32M | $10.36M | $209.76M | $3.46M | $-1.28M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-2.57M | $29.51M | $-6.08M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $30.81M | $-1.09M | $63.00M | $30.75M | $54.18M | $12.31M | $51.27M | $-68.59M | $-5.29M | $-12.64M | $-104.69M | $-358.83M | $451.54M | $28.26M | $39.08M | $-33.26M | $-25.29M | $46.69M | $23.96M | $-23.64M |
| Cash at End of Period | $276.77M | $245.97M | $247.05M | $184.05M | $153.30M | $99.12M | $86.81M | $35.55M | $104.14M | $109.42M | $122.06M | $226.75M | $585.58M | $134.04M | $105.77M | $66.70M | $99.96M | $125.24M | $78.55M | $54.59M |
| Cash at Beginning of Period | $245.97M | $247.05M | $184.05M | $153.30M | $99.12M | $86.81M | $35.55M | $104.14M | $109.42M | $122.06M | $226.75M | $585.58M | $134.04M | $105.77M | $66.70M | $99.96M | $125.24M | $78.55M | $54.59M | $78.23M |
| Operating Cash Flow | $33.13M | $53.92M | $53.24M | $49.10M | $47.58M | $44.44M | $43.50M | $19.13M | $42.04M | $42.65M | $29.81M | $30.78M | $23.21M | $60.29M | $30.13M | $12.08M | $46.67M | $39.78M | $-15.62M | $6.21M |
| Capital Expenditure | $-2.12M | $-4.09M | $-1.59M | $-2.84M | $-1.80M | $-3.39M | $-3.40M | $-6.57M | $-5.49M | $-5.18M | $-11.73M | $-7.67M | $-9.17M | $-13.08M | $-10.55M | $-13.07M | $-14.41M | $-7.76M | $-8.91M | $-6.72M |
| Free Cash Flow | $31.01M | $49.83M | $51.65M | $46.27M | $45.79M | $41.04M | $40.09M | $12.56M | $36.55M | $37.47M | $18.07M | $23.11M | $14.05M | $47.21M | $19.58M | $-992.00K | $32.26M | $32.02M | $-24.53M | $-516.00K |
Pacira BioSciences Dividends
Explore Pacira BioSciences's dividend history, including dividend yield, payout ratio, and historical payments.
Pacira BioSciences News
Read the latest news about Pacira BioSciences, including recent articles, headlines, and updates.
Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee
-- Poster to be presented at OARSI World Congress on Osteoarthritis -- BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the upcoming presentation of new 104-week data in support of its locally administered gene therapy candidate, PCRX-201 (enekinragene inzadenovec). The data is being presented at the 2025 Osteoarthritis Research Society International (OARSI) World Congress in Incheon, South Korea, April 24-27.
DOMA Perpetual Supports Pacira's New $300 Million Share Repurchase Authorization as a Meaningful Step to Enhance Value for Shareholders
DOMA Perpetual Believes Pacira's Stock Is Undervalued, Presenting an Opportunity to Execute the Largest Buyback in the Company's History MIAMI , April 21, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC (collectively with its affiliates, "DOMA Perpetual" or "We") is a fundamentals-based, value-oriented asset management firm which beneficially owns approximately 4.2% of the outstanding shares of common stock of Pacira BioSciences, Inc. (NASDAQ: PCRX ) ("Pacira" or the "Company"). Following constructive engagement with Pacira, DOMA Perpetual believes the Company's new capital allocation announcementi represents the Board's firm commitment to enhancing shareholder value.
Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / April 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRA). Investors who purchased Pacira securities prior to August 2, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PCRA.
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on April 2, 2025 to 18 new employees under Pacira's Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.
Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act
PCRX focuses on non-opioid pain management with Exparel, Zilretta, and iovera, delivering targeted pain relief with fewer side effects. A key secular tailwind for them comes from the NOPAIN Act, which creates separate reimbursement and grows access to non-opioid therapies. Also, PCRX's PCRX-201 is a promising new gene therapy for knee osteoarthritis, which so far has shown promising results and targets a sizeable TAM.
Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL
-- Fresenius Kabi licensed to sell volume-limited amounts of generic bupivacaine liposome injectable suspension in the U.S. no earlier than a confidential date in 2030 -- -- Fresenius also licensed to sell generic bupivacaine liposome injectable suspension in the U.S. without volume limitations beginning in 2039 --
Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee
-- Novel, locally administered gene therapy designed to boost cellular production of anti-inflammatory protein IL-1Ra in the knee -- -- Initial topline results from two-part, randomized, double-blind, active-controlled study expected late 2026 -- BRISBANE, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the first patient has been dosed in the Phase 2 ASCEND study of PCRX-201 (enekinragene inzadenovec) for the treatment of osteoarthritis, or OA, of the knee.
Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
BRISBANE, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the 24th Annual Needham Virtual Healthcare Conference at 11:45 AM ET on Monday, April 7, 2025.
Pacira BioSciences: Back On An Uptrend After Positive Developments
Pacira BioSciences, Inc.'s stock is up 33% since my last “Buy” rating, driven by strategic moves and market overreaction correction. The company has secured a new patent for its lead pain therapeutic, Exparel, delaying generic market entrants, and potentially protecting its market share until mid-next decade. Vertex's Journavx launch may boost awareness for non-opioid pain relief, benefiting Pacira's Exparel under the NOPAIN Act.
Levi & Korsinsky Notifies Shareholders of Pacira BioSciences, Inc. (PCRX) of a Class Action Lawsuit and an Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / March 14, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=136169&wire=1 or contact Joseph E. Levi, Esq.
Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual
-- No Shareholder Action Required at This Time -- PARSIPPANY, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today confirmed that DOMA Perpetual Capital Management LLC (“DOMA”) has nominated three candidates to stand for election to the Pacira Board of Directors (the “Board”) at the Company's 2025 Annual Meeting of Stockholders.
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Pacira BioSciences, Inc.(PCRX) Shareholders
NEW YORK, NY / ACCESS Newswire / March 14, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=136135&wire=1 or contact Joseph E. Levi, Esq.
Shareholders That Lost Money on Pacira BioSciences, Inc. (PCRX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
NEW YORK, NY / ACCESS Newswire / March 14, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=136106&wire=1 or contact Joseph E. Levi, Esq.
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences
Pacira's Stock is Down 76% Over the Last Decade, While the Board and Management Have Enriched Themselves at a Cost of Half a Billion Dollars, Roughly 50% of the Current Market Cap Under CEO and Board Member Frank Lee, the Stock Price Has Declined 33%; He is Pushing for Higher Compensation Packages for Management While Burdening Shareholders with New Risks; DOMA Believes His Views on Capital Allocation Are Misaligned With Shareholder Interest and He Has No Track Record of Creating Shareholder Value Change to the Board's Composition is Critical to Accelerate Shareholder Return and to Correct a Decade of Corporate Abuse and Lack of Stock Price Returns DOMA's Three Highly Qualified Nominees Possess Vast Experience in Strategic Capital Allocation, Risk Management, Healthcare Banking and Intellectual Property Law and Litigation MIAMI , March 14, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC ("DOMA Perpetual") is a fundamentals-based, value-oriented investor that, together with the other participants in its solicitation (collectively "DOMA" or "we"), beneficially owns approximately 4.2% of the outstanding shares of common stock of Pacira BioSciences (NASDAQ: PCRX) ("Pacira" or the "Company").i DOMA today announced its nomination of three highly skilled director candidates to Pacira BioSciences Board of Directors (the "Board"): Joseph Kromholz, Philip Pucciarelli and Eric de Armas. DOMA believes electing these nominees is critical to address the Board's lack of financial sophistication and legal expertise and to correct its value-destroying capital allocation strategy.
PCRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Pacira BioSciences, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESS Newswire / March 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Pacira securities between August 2, 2023 and August 8, 2024, both dates inclusive (the "Class Period").
Lost Money on Pacira BioSciences, Inc.(PCRX)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=135913&wire=1 or contact Joseph E. Levi, Esq.
PCRX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 14 Deadline in Securities Class Action – PCRX
NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023 and August 8, 2024, both dates inclusive (the “Class Period”), of the important March 14, 2025 lead plaintiff deadline.
Shareholders of Pacira BioSciences, Inc. Should Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights - PCRX
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=135886&wire=1 or contact Joseph E. Levi, Esq.
Levi & Korsinsky Reminds Pacira Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 - PCRX
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=135840&wire=1 or contact Joseph E. Levi, Esq.
Class Action Filed Against Pacira BioSciences, Inc. (PCRX) Seeking Recovery for Investors - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=135831&wire=1 or contact Joseph E. Levi, Esq.
Pacira BioSciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights – PCRX
NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit.
PCRX LAWSUIT ALERT: Levi & Korsinsky Notifies Pacira BioSciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=135777&wire=1 or contact Joseph E. Levi, Esq.
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Pacira To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Pacira between August 2, 2023 and August 8, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , March 13, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) and reminds investors of the March 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for PCRX.